In the Absence of Objective Measures for ALS, Caregivers Are the Only Witnesses. We Shouldn’t Have To Be.

Why It Matters

Accurate, real‑time measurement can accelerate ALS drug development and reduce patient burden, directly influencing therapeutic success and healthcare costs.

Key Takeaways

• ALSFRS‑R lacks granularity for daily fluctuations
• Actigraphy offers continuous objective movement data
• Trial failures may stem from insensitive outcome measures
• Patients willing to wear multiple wearables for monitoring
• Regulatory hurdles slow digital endpoint adoption

Pulse Analysis

The ALS Functional Rating Scale‑Revised has been the cornerstone of disease‑progression assessment for decades, yet its 12‑item snapshot fails to capture the ebb and flow that patients experience each day. Subtle improvements, such as a fleeting return of limb movement, disappear into the noise of a monthly score. This lack of resolution not only hampers clinicians’ ability to tailor care but also blurs the signal in clinical trials, making it difficult to discern whether a therapeutic agent is truly effective.

Actigraphy and other wearable sensors can record minute‑by‑minute activity, providing an objective, continuous readout of motor function. In a recent informal survey of 69 ALS patients, every respondent expressed willingness to wear an actigraphy device, and 80 % would accept multiple sensors. Such acceptance reflects a broader cultural shift toward at‑home health monitoring and offers a path to reduce costly, exhausting clinic visits. Continuous data streams could reveal early trends, differentiate drug‑induced stabilization from natural variability, and empower caregivers with real‑time insights.

Regulatory agencies demand rigorously validated endpoints, a hurdle that has slowed digital adoption despite clear patient benefit. The recent approvals of Amylyx’s Relyvrio and the SOD1‑targeted antibody Qalsody illustrate how trials can succeed on biomarker data while stumbling on ALSFRS‑R outcomes. Embedding actigraphy as a co‑primary endpoint could provide complementary evidence, satisfying both safety and efficacy criteria. As the ALS therapeutic landscape evolves, integrating continuous, objective measures will be essential to capture true clinical impact and avoid discarding promising treatments due to inadequate assessment tools.